The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Abstract

The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.

Keywords

Chinese Society of Clinical Oncology (CSCO) / gastric cancer / diagnosis / surgery / neoadjuvant / adjuvant / radiotherapy / chemotherapy / targeted therapy / immunotherapy

References

[1] Seevaratnam, R. et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta-analysis. Gastric Cancer. 2012;15(Suppl 1):S3-18.

[2] Amin, M. B. et al. AJCC Cancer Staging Manual, 8th ed.New York: Springer; 2017.

[3] Allum, W. H. et al. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60:1449-1472.

[4] Yang, Y. et al. A new radiomics approach combining the tumor and peri-tumor regions to predict lymph node metastasis and prognosis in gastric cancer. Gastroenterol Rep (Oxf). 2023;7:goac080,

[5] Dong, D. et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann Oncol. 2019;30:431-438.

[6] Mocellin, S. & Pasquali, S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;CD009944,

[7] Kim, Y. K. et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (</= 1.5 cm in diameter). Invest Radiol. 2012;47:159-166.

[8] Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.

[9] Seymour, L. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-e152.

[10] Wang, Z. C. et al. CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. Diagn Interv Radiol. 2017;23:257-262.

[11] Giganti, F. et al. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2014;40:1147-1157.

[12] Tang, L. et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70:1198-1204.

[13] Jiang, Y. et al. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg. 2020.

[14] Xu, G. et al. Risk factors for under-diagnosis of gastric intraepithelial neoplasia and early gastric carcinoma in endoscopic forceps biopsy in comparison with endoscopic submucosal dissection in Chinese patients. Surg Endosc. 2016;30:2716-2722.

[15] Zhou, P. H. et al. Conventional vs. waterjet-assisted endoscopic submucosal dissection in early gastric cancer: a randomized controlled trial. Endoscopy. 2014;46:836-843.

[16] Bosman FT, Carneiro F, Hruban RH & Theise ND. IARC Press, France, 2010.

[17] Nagtegaal, I. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76.

[18] Sun, Q., Fan, X. S. & Huang, Q. Suggestions on the pathological standardization of endoscopic mucosal dissection specimens for early proximal gastric cancer and precancerous lesions (Chinese). Zhonghua Xiaohua Neijing Zazhi. 2016;33:585-588.

[19] Amin, M. B. et al. AJCC Cancer Staging Manual. 8th ed.New York: Springer; 2017.

[20] Nagtegaal, I. D. et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182-188.

[21] Lauren, P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand. 1965;64:31-49.

[22] Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167-192.

[23] Xue, W. C., Fan, X. S. & Meng, G. Expert Committee Consensus. Selection of immunohistochemical markers for gastric cancer (2014) (Chinese). Linchuang yu Shiyan Binglixue Zazhi. 2014;000:951-953.

[24] Expert Committee on Safety Management of Anti-neoplastic Drugs of Chinese Society of Clinical Oncology, Society of Gastric Cancer of Chinese Anti-Cancer Association, Society of Pathology of Chinese Anti-Cancer Association. Consensus of Chinese experts on molecular targeted therapy for HER2 positive advanced gastric cancer (2016) (Chinese). Linchuang Zhongliuxue Zazhi. 2016;21:831-839.

[25] Sheng, W. Q. et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24:2360-2364.

[26] Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.

[27] Qiu, M. Z. et al. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer. 2014;134:2468-2477.

[28] Wang, D. S. et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2019;68:1152-1161.

[29] Wang, H. et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92-100.

[30] Expert Committe Consensus. Guidelines for HER2 detection in gastric cancer (2016) (Chinese). Zhonghua Binglixue Zazhi. 2016;45 (8):528-532.

[31] Shitara, K. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet. 2018;392:123-133.

[32] Chao Yee, Yang S, Zhang Y, Shen Zhirong, Wu Xikun, Wang Jin, Quiroz Michelle, Nielsen Alma, Liu Chunyan, Desai Jayesh. Investigation of PD-L1 expression and tislelizumab efficacy in gastroesophageal adenocarcinoma using a novel tumor and immune cell score with VENTANA PD-L1 (SP263) assay and Combined Positive Score (CPS). Annals of Oncology. 2020;31:S300,

[33] Moehler, M. H. et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Journal of Clinical Oncology. 2023;41:286-286.

[34] Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet. 2020;396:635-648.

[35] Gotoda, T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10:1-11.

[36] Hasuike, N. et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018;21:114-123.

[37] Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 24. 2021. p. 1-21.

[38] Abdelfatah, M. M. et al. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta-analysis. Gastrointest Endosc. 2018;87:338-347.

[39] Hatta, W. et al. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: "eCura system". Am J Gastroenterol. 2017;112:874-881.

[40] Fukase, K. et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392-397.

[41] Choi, J. M. et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc. 2018;88:475-485 e472.

[42] National Health and Family Planning Commission of the People's Republic of China. Guidelines for standardized diagnosis and treatment of gastric cancer (trial implementation) (Chinese). Manxingbingxue Zazhi. 2013;:47-51.

[43] Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1-19.

[44] Sasako, M. et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7:644-651.

[45] Kurokawa, Y. et al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann Surg. 2021;274:120-127.

[46] Biondi, A. et al. Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer? Eur J Surg Oncol. 2015;41:779-786.

[47] Lin, J. X. et al. Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial. JAMA surgery. 2023;158:10-18.

[48] Sasada, S. et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. Anticancer Res. 2009;29:3347-3351.

[49] Aoyagi, K. et al. Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2:81-86.

[50] Sano, T. et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017;265:277-283.

[51] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101-112.

[52] Jiao, X. et al. Analysis of risk factors for station 14v lymph node metastasis in advanced gastric cancer (Chinese). Zhonghua Xiaohua Waike Zazhi. 2014;13:30-33.

[53] Liang, Y. X. et al. Significance of station 14v lymph node dissection for patients with advanced gastric cancer undergoing D2 lymphadenectomy (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16:632-636.

[54] Eom, B. W. et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408-416.

[55] Shen, D. F. et al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14:936-938.

[56] Eom, B. W. et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669-2675.

[57] Eto, K. et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21:703-709.

[58] Sasako, M. et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-462.

[59] Yang, H. K. et al. Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial. The lancet. Gastroenterology & hepatology. 2021;6:120-127.

[60] Katai, H. et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142-151.

[61] Kim, H. H. et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. JAMA Oncol. 2019;5:506-513.

[62] Hyung, W. J. et al. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multicenter phase II clinical trial, KLASS 03. Gastric Cancer. 2019;22:214-222.

[63] Katai, H. et al. Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer. 2019;22:999-1008.

[64] Liu, F. et al. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020;6:1590-1597.

[65] Yu, J. et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA. 2019;321:1983-1992.

[66] Hyung, W. J. et al. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. J Clin Oncol. 2020;38:3304-3313.

[67] Li, Z. et al. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. JAMA Surg. 2019;154:1093-1101.

[68] Shin, H. J. et al. Long-term Comparison of Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Propensity Score-weighted Analysis of 2084 Consecutive Patients. Ann Surg. 2020;

[69] Li, Z. Y. et al. Robotic Gastrectomy Versus Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Cohort Study of 5402 Patients in China. Ann Surg. 2023;277:e87-e95.

[70] Lu, J. et al. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial. Ann Surg. 2021;273:858-867.

[71] Li, Z. et al. A comparative study on perioperative outcomes between robotic versus laparoscopic D2 total gastrectomy. International journal of surgery. 2022;102, 106636,

[72] Kang, K. C. et al. Comparison of Billroth I and Billroth II reconstructions after laparoscopy-assisted distal gastrectomy: a retrospective analysis of large-scale multicenter results from Korea. Surg Endosc. 2011;25:1953-1961.

[73] Shiraishi, N. et al. Gastric tube reconstruction prevented esophageal reflux after proximal gastrectomy. Gastric Cancer. 1998;1:78-79.

[74] Kim, H. H. et al. Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. J Clin Oncol. 2014;32:627-633.

[75] Nunobe, S. et al. Billroth 1 versus Roux-en-Y reconstructions: a quality-of-life survey at 5 years. International journal of clinical oncology. 2007;12:433-439.

[76] Hwang, S.H. et al. Short-Term Outcomes of Laparoscopic Proximal Gastrectomy With Double-Tract Reconstruction Versus Laparoscopic Total Gastrectomy for Upper Early Gastric Cancer: A KLASS 05 Randomized Clinical Trial. J Gastric Cancer. 2022;22:94-106.

[77] Chinese consensus on digestive tract reconstruction after proximal gastrectomy. Chinese Journal of Gastrointestinal Surgery. 2020;23.

[78] Liang, H. Visual Lectures on Operation For Gastric Cancer (Chinese). May 1, 2013 edn, Tianjin Science and Technology Translation Publishing Co., Ltd; 2013.

[79] Fein, M. et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg. 2008;247:759-765.

[80] Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-321.

[81] Lee, J. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-273.

[82] Yoshida, K. et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296-1304.

[83] Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-4393.

[84] Kodera, Y. et al. A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). Journal of Clinical Oncology. 2018;36:4007-4007.

[85] Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081-1092.

[86] Park, S. H. et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial(). Ann Oncol. 2021;32:368-374.

[87] Wang, Z. X. et al. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. Br J Surg. 2017;104:1226-1234.

[88] Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.

[89] Park, S. H. et al. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. J Clin Oncol. 2015;33:3130-3136.

[90] Stiekema, J. et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21:1107-1114.

[91] Sakuramoto, S. et al. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. New England Journal of Medicine. 2007;357:1810-1820.

[92] Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.

[93] D'Ugo, D., Rausei, S., Biondi, A. & Persiani, R. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009;10:191-195.

[94] Kim, Y. W. et al. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2016;19:586-596.

[95] Wang, X. et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114:1326-1333.

[96] Kang, Y. K. et al. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021;39:2903-2913.

[97] Zhang, W. et al. Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study. Journal of Clinical Oncology. 2022;40:4031-4031.

[98] Sumpter, K. et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976-1983.

[99] Li, Z. Y. et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:793-799.

[100] Kochi, M. et al. Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer. Am J Clin Oncol. 2017;40:17-21.

[101] Li, T. & Chen, L. Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14:104-106.

[102] Al-Batran, S. E. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948-1957.

[103] Andre, T. et al. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2023;41:255-265.

[104] Pietrantonio, F. et al. INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC). Journal of Clinical Oncology. 2023;41:358-358.

[105] Al-Batran, S.-E. et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. Journal of Clinical Oncology. 2022;40:4003-4003.

[106] Cats, A. et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616-628.

[107] Mita, K. et al. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. J Gastrointest Surg. 2017;21:1993-1999.

[108] Roberts, P. et al. Systematic review of pancreaticoduodenectomy for locally advanced gastric cancer. Gastric Cancer. 2012;15 Suppl 1:S108-115.

[109] Xiao, L. et al. Extended multi-organ resection for cT4 gastric carcinoma: A retrospective analysis. Pak J Med Sci. 2013;29:581-585.

[110] Pietrantonio, F. et al. Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019;37:3392-3400.

[111] Bajetta, E. et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373-1378.

[112] Kim, J. W. et al. Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Res Treat. 2020;52:1178-1187.

[113] Leong, T. et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532,

[114] Slagter, A. E. et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18:877,

[115] Ikoma, N. et al. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Annals of surgical oncology. 2016;23:4332-4337.

[116] Ychou, M. et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721.

[117] Shapiro, J. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090-1098.

[118] Wang, X. et al. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiotherapy in Locally Advanced Gastric Adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2018;102:S29-S30.

[119] Stahl, M. et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-856.

[120] Ajani, J. A. et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953-3958.

[121] Schuhmacher, C. et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218.

[122] Wang, X. et al. Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial). Journal of Clinical Oncology. 2020;38:280-280.

[123] Wang, Y. et al. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer. 2018;18:702,

[124] Petrelli, F. et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Gastric Cancer. 2019;22:245-254.

[125] Reynolds, J. et al. Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis. Journal of Clinical Oncology. 2023;41:295-295.

[126] van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-2084.

[127] Tepper, J. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.

[128] Khushalani, N. I. et al. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20:2844-2850.

[129] Ajani, J. A. et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23:1237-1244.

[130] Ajani, J. A. et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953-3958.

[131] Hu, J. B., Sun, X. N., Gu, B. X., Wang, Q. & Hu, W. X. Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients. Oncology research and treatment. 2014;37:11-16.

[132] Inoue, T. et al. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. Annals of surgical oncology. 2012;19:2937-2945.

[133] Wang X, Zao DB, Jin J, et al. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results. J Radiat Oncol Biol Phys. 2016;96, Supplement 32.

[134] Wang, X. et al. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. Br J Cancer. 2018;118:338-343.

[135] Ajani, J. A. et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774-2780.

[136] A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer. 1982;49:1771-1777.

[137] Gunderson, L. L. et al. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 1983;9:965-975.

[138] Mizrak Kaya, D. et al. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018;98:23-29.

[139] Li, R. et al. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer. J Natl Compr Canc Netw. 2018;16:950-958.

[140] Liu, Y. et al. Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer. Int J Radiat Oncol Biol Phys. 2017;98:1096-1105.

[141] Moertel, C. G., Childs, D. S., Reitemeier, R. J., Colby, M. Y., & Holbrook, M. A. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2:865-867.

[142] Kono, K. et al. 1393P Phase I/II clinical trial of combination of anti-PD-1 mAb, nivolumab with radiotherapy for unresectable and recurrent gastric cancer who failed to standard chemotherapy. Annals of Oncology. 2021;32:S1053-S1054.

[143] Wei, J. et al. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer management and research. 2022;14:2007-2015.

[144] Tang, Z. et al. The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction. Nat Commun. 2022;13:6807,

[145] Zhu, M. et al. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. Clin Cancer Res. 2022;28:3021-3031.

[146] Minn, A. Y. et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010;116:3943-3952.

[147] Wang, X. et al. Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT). Med Dosim. 2013;38:395-400.

[148] Wagner, A. D. et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903-2909.

[149] Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-1442.

[150] Hiramoto, S. et al. Efficacy of palliative radiotherapy and chemo-radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction. Int J Clin Oncol. 2018;23:1090-1094.

[151] Coia, L. R., Paul, A. R. & Engstrom, P. F. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer. 1988;61:643-649.

[152] Kim, M. M. et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47:421-427.

[153] Al-Batran, S. E. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435-1442.

[154] Kang, Y. K. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666-673.

[155] Koizumi, W. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215-221.

[156] Hall, P. S. et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7:869-877.

[157] Luo, H. Y. et al. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56:94-100.

[158] Lu, Z. et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21:782-791.

[159] Van Cutsem, E. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.

[160] Wang, J. et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19:234-244.

[161] Xu, R. H. et al. S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial. Journal of Clinical Oncology. 2019;37, 4017,

[162] Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141-148.

[163] Lin, R. et al. POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial. Journal of Clinical Oncology. 2019;37:4035-4035.

[164] Yamada, Y. et al. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4:501-510.

[165] He, M. M. et al. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemother Pharmacol. 2017;79:69-79.

[166] Zhou, C. F. et al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem. 2013;13:235-241.

[167] Moehler, M. et al. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. J Clin Oncol. 2021;39:966-977.

[168] Hwang, I. G. et al. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017;8:170-175.

[169] Hall, P. S. et al. A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017;116:472,

[170] Hawkes, E. et al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer. 2011;47:1146-1151.

[171] Hironaka, S. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438-4444.

[172] Shitara, K. et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277-287.

[173] Shitara, K. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437-1448.

[174] Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.

[175] Li, Q. et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7:50656-50665.

[176] Nishikawa, K. et al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naive patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102). Int J Cancer. 2017;140:188-196.

[177] Qin, S. et al. Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non-interventional registry study (EVIDENCE). Oncologist. 2021;

[178] Janjigian, Y. Y. et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821-831.

[179] Janjigian, Y. Y. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727-730.

[180] Tabernero, J. et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372-1384.

[181] Hecht, J. R. et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC–A Randomized Phase III Trial. J Clin Oncol. 2016;34:443-451.

[182] Satoh, T. et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol. 2014;32:2039-2049.

[183] Peng, Z. et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41:1173-1182.

[184] Shitara, K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382:2419-2430.

[185] Ku, G. Y. et al. 1205MO Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen. Annals of Oncology. 2022;33, S1100,

[186] Kang YK, Shah MA, Ohtsu A, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016;34:a5.

[187] Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39.

[188] Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-1235.

[189] Xu, R. H. et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. The lancet. Gastroenterology & hepatology. 2021;6:1015-1024.

[190] Li, J. et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34:1448-1454.

[191] Xu J., Pan H.Y., et al. Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Annals of Oncology. 2021;32:S1283-S1346.

[192] Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27-40.

[193] Xie, T. et al. Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11, 646355,

[194] Zhao, J. J. et al. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. J Clin Oncol. 2022;40:392-402.

[195] Moehler, M. H. et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). Journal of Clinical Oncology. 2023;41:286-286.

[196] Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234-247.

[197] Shitara, K. et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:1571-1580.

[198] Latham, A. et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol. 2019;37:286-295.

[199] Akagi, K. et al. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci. 2021;112:1105-1113.

[200] Lenz, H. J. et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II Check-Mate 142 Study. J Clin Oncol. 2022;40:161-170.

[201] Li, J. et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14:95,

[202] Li, J. et al. A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors. Journal of Clinical Oncology. 2021;39:2569-2569.

[203] Qin, S. et al. Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study. Journal of Clinical Oncology. 2021;39:2566-2566.

[204] Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461-2471.

[205] Qiu, M. Z. et al. Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients. Therapeutic advances in medical oncology. 2020;12, 1758835920937434,

[206] Xie, T. et al. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. Journal of immunotherapy (Hagerstown, Md. : 1997). 2020;43:139-144.

[207] Shitara, K. et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+ (CLDN18.2+) /HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. Journal of Clinical Oncology. 2023;41:LBA292-LBA292.

[208] Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28:1189-1198.

[209] QI, C. et al. Safety, tolerability, and preliminary efficacy results in patients with advanced gastric/gastroesophageal junction adenocarcinoma from a phase Ib/II study of CLDN18.2 CAR T-cell therapy (CT041). Journal of Clinical Oncology. 2022;40:4017-4017.

[210] Japanese Gastric Cancer, A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1-25.

[211] Leake, P. A. et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012; 15 Suppl 1:S27-37.

[212] Jamel, S. et al. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta-analysis. Gastric Cancer. 2018;21:10-18.

[213] Coccolini, F. et al. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol. 2016;42:1261-1267.

[214] Lopez-Basave, H. N. et al. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Cir Cir. 2018;86:277-284.

[215] Kodera, Y. et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15:335-337.

[216] Kano, K. et al. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. Int J Clin Oncol. 2017;22:887-896.

[217] Coccolini, F. et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40:12-26.

[218] Yamaguchi, H. et al. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119:3354-3358.

[219] Yoshida, K., Yamaguchi, K., Okumura, N., Tanahashi, T. & Kodera, Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19:329-338.

[220] Ishigami, H. et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018;36:1922-1929.

[221] Niibe, Y. & Hayakawa, K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40:107-111.

[222] Milano, M. T., Katz, A. W., Zhang, H. & Okunieff, P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83:878-886.

[223] Hellman, S. & Weichselbaum, R. R. Oligometastases. Journal of Clinical Oncology. 1995;13:8-10.

[224] Badgwell, B. et al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009;16:42-50.

[225] Xu, C. et al. Concurrent involved-field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence. Journal of Cancer Research and Therapeutics. 2014;10:267-271.

[226] Yuan, S. T. et al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. Am J Clin Oncol. 2015;38:130-134.

[227] Xie, J. et al. Docetaxel, capecitabine and concurrent radiotherapy for gastric cancer patients with postoperative locoregional recurrence. Tumori. 2015;101:433-439.

[228] Maruyama, K. et al. Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9:51-66.

[229] Ohira, M. et al. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22:2424-2433.

[230] Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma (Japanese). 13 edn. JinYuan; 1999.

[231] Sano, T. et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy–Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22:2767-2773.

[232] Fujitani, K. et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309-318.

[233] Yoshikawa, T. et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015-1022.

[234] Tsuburaya, A. et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653-660.

[235] Ito, S. et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322-331.

[236] Katayama, H. et al. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer. 2019;22:1301-1307.

[237] Wang, Y. et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73:1155-1161.

[238] Thelen, A. et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34:1328-1334.

[239] Li, W. et al. Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study. Cancer Manag Res. 2019;11:2007-2013.

[240] Liao, Y. Y. et al. Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg. 2017;17:14,

[241] Gavriilidis, P., Roberts, K. J., de'Angelis, N. & Sutcliffe, R. P. Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta-Analysis. J Clin Med Res. 2019;11:600-608.

[242] Markar, S. R. et al. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016;263:1092-1101.

[243] Montagnani, F. et al. Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018;69:11-20.

[244] Kataoka, K. et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer. 2017;20:904-912.

[245] Guner, A. et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19:951-960.

[246] Zhou, F. et al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2017;33:830-835.

[247] Fukami, Y. et al. Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases. Int J Surg. 2017;46:79-84.

[248] Yamakado, K. et al. Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer. J Vasc Interv Radiol. 2005;16:1747-1751.

[249] Liu, S. F. et al. Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chinese medical journal. 2015;128:2194-2201.

[250] Goodman, K. A. et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78:486-493.

[251] Oki, E. et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968-976.

[252] Tang, K. et al. Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long-term survival: Systematic review and pooled analysis. Medicine (Baltimore). 2018;97, e13525,

[253] Brieau, B. et al. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Dig Liver Dis. 2016;48:441-445.

[254] Cho, J. H. et al. Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat. 2015;47:697-705.

[255] Yan, D. et al. Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single-center Experience. J Cancer. 2018;9:4197-4203.

[256] Shinohara, T., Maeda, Y., Hamada, T. & Futakawa, N. Survival benefit of surgical treatment for liver metastases from gastric cancer. J Gastrointest Surg. 2015;19:1043-1051.

[257] Markar, S. R. et al. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016;263:1092-1101.

[258] Aurello, P. et al. The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review. Anticancer Res. 2022;42:25-33.

[259] Zhou F, Yu XL, Liang P, et al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2017;33:830-835.

[260] Hwang, J. E. et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2014;31:25-32.

[261] Aurello, P. et al. Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review. 2018;. Oncol Res Treat 41:644-649.

[262] Rosa, F. et al. Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience. World J Surg. 2016;40:921-928.

[263] Olver, I. et al. Supportive care in cancer-a MASCC perspective. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020;28:3467-3475.

[264] Lu, Z. et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021;39:748-756.

[265] Guo, Z. Q. et al. Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. Support Care hCancer. 2020;28:373-380.

[266] Guidelines Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) guidelines for nutritional therapy in patients with malignant tumor. Beijing: People's Medical Publishing House; 2019.

[267] Gastric Cancer Committee of the China Anti-Cancer Association Committee and the Gastrointestinal Surgery Committee of the Chinese Society of Surgery. Chinese Expert Consensus on the perioperative nutritional therapy for gastric cancer (2019 Edition). Zhongguo Shiyong Waike Zazhi. 2020, 40 (2):145-151.

[268] Kondrup, J., Rasmussen, H. H., Hamberg, O. & Stanga, Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22:321-336.

[269] Bauer, J., Capra, S. & Ferguson, M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56:779-785.

[270] Mortensen, K. et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101:1209-1229.

[271] Shi, H. P. et al. Guidelines for nutritional therapy in patients with gastric cancer (Chinese). Zhongliu Daixie yu Yingyang Dianzi Zazhi. 2015;:488-491.

[272] Kim, Y. I. & Choi, I. J. Endoscopic management of tumor bleeding from inoperable gastric cancer. Clinical endoscopy. 2015;48:121-127.

[273] Chen, Y. et al. Clinical application of interventional embolization in tumor-associated hemorrhage. Annals of translational medicine. 2020;8:394,

[274] Bian, S. B., Shen, W. S., Xi, H. Q., Wei, B. & Chen, L. Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: A Meta-analysis Comparison of Gastrojejunostomy with Endoscopic Stenting. Chinese medical journal. 2016;129:1113-1121.

[275] Liu Hao, X. Q., Ma Fu-Hai, Ma Shuai, Li Yang, Li Wei-Kun, Tian Yan-Tao. The clinical value of totally laparoscopic stomach-partitioning gastrojejunostomy for malignant gastric outlet obstruction. Chinese Journal of Oncology. 2020;42:445-448.

[276] Iqbal, U. et al. EUS-guided gastroenterostomy for the management of gastric outlet obstruction: A systematic review and meta-analysis. Endosc Ultrasound. 2020;9:16-23.

[277] Smyth, E. C. et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38-v49.

[278] Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167-192.

[279] Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1-21.

[280] Ajani, J. et al. (2020).

[281] Association Japanese Gastric Cancer. Japanese Classifcation of Gastric Carcinoma (Japanese). 15th ed. Tokyo: Kanehara Shuppan; 2017.

[282] Japanese Gastric Cancer, A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1-19.

[283] Kluijt, I. et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial cancer. 2012;11:363-369.

[284] van der Post, R. S. et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. Journal of medical genetics. 2015;52:361-374.

[285] de Boer, W. B., Ee, H. & Kumarasinghe, M. P. Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. Am J Surg Pathol. 2018;42:1-8.

[286] Worthley, D. L. et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61:774-779.

[287] Hansford, S. et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1:23-32.

[288] Majewski, I. J. et al. An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229:621-629.

[289] Syngal, S. et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223-262; quiz 263,

[290] Capelle, L. G. et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138:487-492.

[291] Blair, V. R. et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21:e386-e397.

[292] Lerner, B. A., Xicola, R. M., Rodriguez, N. J., Karam, R. & Llor, X. Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants. Journal of medical genetics. 2023;60:36-40.

[293] Coudert, M. et al. First estimates of diffuse gastric cancer risks for carriers of CTNNA1 germline pathogenic variants. Journal of medical genetics. 2022;59:1189-1195.

[294] Gayther, S. A. et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086-4089.

[295] Liu, Z. X. et al. Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer. JAMA Netw Open. 2022;5, e2245836,

[296] Gamble, L. A. et al. Association Between Hereditary Lobular Breast Cancer Due to CDH1 Variants and Gastric Cancer Risk. JAMA surgery. 2022;157:18-22.

RIGHTS & PERMISSIONS

2023 The Authors. Cancer Communications published by JohnWiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.